Press Release Details

Mersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 23, 2017

CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Dolaflexin® platform, today announced that it will report preclinical data on  its second product candidate, XMT-1536, in a poster to be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutic, held October 26-30 in Philadelphia. Presentation details are as follows:

Title:     Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting
antibody-drug conjugate (ADC), in an unselected panel of human primary
ovarian mouse xenograft models
Session:     Poster Session B, Therapeutic Agents: Biological
Presenter:     Rebecca Mosher, M.D., Executive Director, Translational Medicine
Date and Time:     Sunday, October 29, 2017, 12:30 p.m. - 4:00 p.m. ET
Poster/Abstract:     119/B119


About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients.  Mersana’s lead product candidate, XMT-1522, is in Phase I clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company expects that its second product candidate, XMT-1536, will enter clinical trials in early 2018. In addition, multiple partners are using Mersana’s leading platform to advance their ADC pipelines.

Media Contact
Paul Kidwell

Investors Contact
Stern Investor Relations, Inc.
Christina Tartaglia
(212) 362-1200

Primary Logo


Source: Mersana Therapeutics, Inc.